The QuantiFERON Monitor


Journal

Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 20 06 2019
revised: 24 11 2019
accepted: 02 02 2020
pubmed: 9 2 2020
medline: 4 2 2021
entrez: 9 2 2020
Statut: ppublish

Résumé

Following allogeneic hematopoietic stem cell transplantation (alloHCT), excessive immunosuppression can be complicated by infection, while inadequate immunosuppression can result in graft-vs-host disease (GVHD). An accurate method to assess overall immune status post HCT is lacking. The QuantiFERON Monitor Whole blood samples were prospectively collected from alloHCT recipients at conditioning followed by days 10, 30, 60, 90, 120, and 180 post-transplant and assayed by the QFM test. IFN-γ levels were correlated to time post HCT and episodes of infection and GVHD. Forty patients were enrolled in the study (68% male; median age 47 years; 58% matched related donors, 42% unrelated; 33% myeloablative). Post-stimulation IFN-γ levels rose steadily over the first 180 days post transplantation. IFN-γ levels were significantly lower in those with active infection compared to those without during the neutropenic period (P < .001). The assay was predictive of CMV reactivation (VL > 1000 copies/mL) post alloHCT (P = .001). This is a promising assay to demonstrate immune recovery and predict risk of infection after alloHCT and may allow tailoring of immunosuppression, antimicrobial treatment, and prophylaxis.

Identifiants

pubmed: 32034973
doi: 10.1111/tid.13260
doi:

Substances chimiques

Reagent Kits, Diagnostic 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13260

Subventions

Organisme : Qiagen Inc

Informations de copyright

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20(6):872-880.
George B, Pati N, Gilroy N, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis. 2010;12(4):322-329.
Gesundheit B, Budowski E, Israeli M, et al. Assessment of CD4 T-lymphocyte reactivity by the Cylex ImmuKnow assay in patients following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010;45(3):527-533.
Sood S, Cundall D, Yu L, et al. A novel biomarker of immune function and initial experience in a transplant population. Transplantation. 2014;97(8):e50-51.
Mian M, Natori Y, Ferreira V, et al. Evaluation of a novel global immunity assay to predict infection in organ transplant recipients. Clin Infect Dis. 2018;66(9):1392-1397.
De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813-1821.
Ljungman P, de la Camara R, Cordonnier C, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008;42(4):227-240.
Mehta RS, Rezvani K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence. 2016;7(8):901-916.

Auteurs

Abby P Douglas (AP)

Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Vic., Australia.
University of Melbourne, Melbourne, Vic., Australia.
Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.

Lijia Yu (L)

University of Melbourne, Melbourne, Vic., Australia.
Immunology Research Centre, St Vincent's Hospital, Melbourne, Vic., Australia.

Vijaya Sundararajan (V)

University of Melbourne, Melbourne, Vic., Australia.
Department of Public Health, Latrobe University, Melbourne, Vic., Australia.

Jeff Szer (J)

University of Melbourne, Melbourne, Vic., Australia.
Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
Department of Clinical Haematology and Bone Marrow Transplant Service, Royal Melbourne Hospital, Melbourne, Vic., Australia.

David Ritchie (D)

University of Melbourne, Melbourne, Vic., Australia.
Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
Department of Clinical Haematology and Bone Marrow Transplant Service, Royal Melbourne Hospital, Melbourne, Vic., Australia.

Monica A Slavin (MA)

Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Vic., Australia.
University of Melbourne, Melbourne, Vic., Australia.
Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.

Joe Sasadeusz (J)

Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Vic., Australia.
University of Melbourne, Melbourne, Vic., Australia.

Kumar Visvanathan (K)

University of Melbourne, Melbourne, Vic., Australia.
Immunology Research Centre, St Vincent's Hospital, Melbourne, Vic., Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH